Moderna secures additional US $ 472 million for COVID-19 vaccination efforts

0
94


Moderna Biotechnology Company Inc. MRNA,
-2,81%
Sunday, announced that the US government has committed up to an additional $ 472 million in its efforts to develop a vaccine against the coronavirus. In a statement, the drugmaker said funding would go to late-stage clinical development, including an expanded Phase 3 study of its vaccine candidate. In April, Moderna received up to $ 483 million from the government’s Biomedical Advanced Research and Development Authority. “Encouraged by the data from Phase 1, we believe our mRNA vaccine can help fight the COVID-19 pandemic and prevent future outbreaks,” Moderna CEO Stéphane Bancel said in a statement. Moderna’s shares have climbed more than 270% this year as it became one of the pioneers in developing a COVID-19 vaccine.

LEAVE A REPLY

Please enter your comment!
Please enter your name here